See more : Asian Star Anchor Chain Co., Ltd. Jiangsu (601890.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Grand Pharmaceutical Group Limited (0512.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Grand Pharmaceutical Group Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Çelebi Hava Servisi A.S. (CLEBI.IS) Income Statement Analysis – Financial Results
- Primavera Capital Acquisition Corporation (PV-UN) Income Statement Analysis – Financial Results
- Texas Gulf Energy, Incorporated (TXGE) Income Statement Analysis – Financial Results
- Crazy Woman Creek Bancorp Incorporated (CRZY) Income Statement Analysis – Financial Results
- Bank of Labor Bancshares, Inc. (BHDB) Income Statement Analysis – Financial Results
Grand Pharmaceutical Group Limited (0512.HK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.grandpharm.com
About Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers pharmaceutical preparations, including cerebro-cardiovascular emergency medicines; respiratory, ophthalmic, anti-infection, and ENT medicines; oncology medicines; and rare disease medicines. It also provides medical devices, such as vascular interventional medical devices comprising paclitaxel releasing coronary balloon dilatation catheters and paclitaxel releasing hemodialysis shunt balloon dilatation catheters; and ophthalmology related devices. In addition, the company offers biotechnology and health products, such as Taurine, amino acid products, steroid products, and bio-pesticides and agricultural antibiotics; and specialized pharmaceutical raw materials and other products, including metronidazole, chloramphenicol, epinephrine, dimethyl sulfate, nitromethane, etc. Further, the company offers agrochemicals, fine chemicals, and chemical medicines; ophthalmic gel and eye drops; steroid hormones active pharmaceutical ingredients and related intermediates; bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. Grand Pharmaceutical Group Limited has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited and changed its name to Grand Pharmaceutical Group Limited in November 2021. Grand Pharmaceutical Group Limited was incorporated in 1995 and is based in Central, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.53B | 9.56B | 8.60B | 6.35B | 6.59B | 5.96B | 4.77B | 3.70B | 3.25B | 3.12B | 2.66B | 2.06B | 1.65B | 1.05B | 545.44M | 269.88M | 49.05M | 42.41M | 46.38M | 63.16M |
| Cost of Revenue | 4.01B | 3.61B | 3.35B | 2.32B | 2.56B | 2.80B | 2.29B | 1.96B | 1.90B | 1.93B | 1.77B | 1.41B | 1.13B | 679.95M | 295.34M | 160.14M | 26.39M | 23.44M | 26.30M | 42.60M |
| Gross Profit | 6.52B | 5.95B | 5.25B | 4.04B | 4.03B | 3.16B | 2.48B | 1.73B | 1.35B | 1.19B | 886.53M | 645.18M | 515.10M | 374.81M | 250.09M | 109.75M | 22.65M | 18.97M | 20.09M | 20.57M |
| Gross Profit Ratio | 61.96% | 62.24% | 61.03% | 63.52% | 61.19% | 53.06% | 51.97% | 46.87% | 41.61% | 38.23% | 33.35% | 31.33% | 31.26% | 35.54% | 45.85% | 40.66% | 46.19% | 44.73% | 43.31% | 32.56% |
| Research & Development | 571.99M | 531.92M | 331.42M | 219.31M | 186.13M | 137.49M | 84.71M | 65.20M | 106.90M | 81.83M | 62.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.23B | 870.03M | 909.62M | 685.24M | 609.62M | 552.51M | 541.26M | 420.79M | 428.95M | 372.44M | 315.54M | 236.99M | 205.91M | 121.97M | 89.72M | 56.23M | 48.29M | 34.96M | 49.61M | 54.67M |
| Selling & Marketing | 2.57B | 2.31B | 2.40B | 1.86B | 2.24B | 1.76B | 1.33B | 902.72M | 641.66M | 608.16M | 456.61M | 340.31M | 261.91M | 207.94M | 114.46M | 61.06M | 26.35M | 0.00 | 0.00 | 0.00 |
| SG&A | 3.80B | 2.90B | 2.90B | 2.31B | 2.68B | 2.31B | 1.87B | 1.32B | 1.07B | 980.59M | 772.14M | 577.30M | 467.82M | 329.91M | 204.18M | 117.29M | 74.63M | 34.96M | 49.61M | 54.67M |
| Other Expenses | 0.00 | 40.25M | 46.16M | 41.08M | 38.37M | 38.67M | 55.62M | 4.61M | 5.42M | 3.18M | 3.72M | 5.74M | -78.08M | 21.63M | 17.24M | -8.66M | -4.46M | -5.41M | -6.52M | -11.13M |
| Operating Expenses | 3.86B | 3.43B | 3.23B | 2.53B | 2.87B | 2.09B | 1.75B | 1.25B | 981.75M | 892.06M | 690.67M | 505.74M | 389.73M | 189.46M | 196.89M | 108.64M | 70.18M | 40.35M | 134.97M | 177.08M |
| Cost & Expenses | 7.87B | 7.04B | 6.58B | 4.84B | 5.42B | 4.89B | 4.04B | 3.21B | 2.88B | 2.82B | 2.46B | 1.92B | 1.52B | 869.41M | 492.23M | 268.77M | 96.57M | 63.79M | 161.27M | 219.67M |
| Interest Income | 7.75M | 19.81M | 74.95M | 18.05M | 11.15M | 188.43M | 170.80M | 169.11M | 128.17M | 98.67M | 63.58M | 5.43M | 4.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 205.15M | 137.49M | 92.96M | 115.42M | 146.50M | 203.30M | 174.43M | 181.68M | 157.16M | 114.09M | 77.63M | 41.80M | 26.41M | 51.96M | 26.85M | 16.06M | 9.23M | 5.75M | 0.00 | 0.00 |
| Depreciation & Amortization | 392.21M | 394.91M | 339.52M | 287.06M | 477.14M | 236.32M | 243.26M | 219.43M | 191.38M | 171.23M | 96.87M | 80.22M | 46.02M | 35.69M | 16.62M | 12.63M | 10.07M | 10.31M | 23.73M | 42.32M |
| EBITDA | 2.97B | 3.09B | 3.10B | 2.41B | 1.86B | 1.32B | 976.63M | 715.07M | 589.10M | 494.92M | 316.67M | 237.54M | 178.61M | 245.81M | 92.25M | 6.01M | -35.98M | 3.65M | -141.00M | -114.19M |
| EBITDA Ratio | 28.17% | 30.46% | 27.43% | 28.28% | 24.93% | 18.94% | 19.06% | 18.32% | 16.90% | 15.10% | 10.77% | 11.38% | 10.43% | 23.31% | 16.91% | 2.23% | -75.01% | -26.11% | -196.52% | -180.80% |
| Operating Income | 2.66B | 2.52B | 2.02B | 1.51B | 1.17B | 892.31M | 665.87M | 457.74M | 357.02M | 300.08M | 189.48M | 157.32M | 125.87M | 185.35M | 53.21M | 6.62M | 47.52M | 6.78M | 102.29M | 145.37M |
| Operating Income Ratio | 25.29% | 26.33% | 23.48% | 23.76% | 17.70% | 14.98% | 13.96% | 12.38% | 11.00% | 9.61% | 7.13% | 7.64% | 7.64% | 17.57% | 9.75% | 2.45% | 96.89% | 15.98% | 220.52% | 230.16% |
| Total Other Income/Expenses | -319.20M | 43.06M | 653.39M | 502.33M | -158.40M | -8.41M | -106.93M | -143.78M | -116.45M | -97.16M | -57.20M | -41.79M | -26.41M | -27.18M | -4.42M | -15.24M | -11.35M | -18.96M | -56.48M | -76.89M |
| Income Before Tax | 2.34B | 2.56B | 2.67B | 2.01B | 1.24B | 883.90M | 558.94M | 313.96M | 240.56M | 202.92M | 132.28M | 115.54M | 99.46M | 158.17M | 48.79M | -22.69M | -56.09M | -12.19M | -108.80M | -156.50M |
| Income Before Tax Ratio | 22.26% | 26.78% | 31.08% | 31.66% | 18.83% | 14.83% | 11.72% | 8.49% | 7.41% | 6.50% | 4.98% | 5.61% | 6.04% | 15.00% | 8.94% | -8.41% | -114.36% | -28.74% | -234.57% | -247.78% |
| Income Tax Expense | 448.76M | 418.64M | 380.80M | 292.37M | 230.49M | 147.46M | 73.18M | 44.60M | 40.16M | 27.20M | 26.99M | 10.83M | 12.79M | 3.89M | 6.87M | -4.00K | -2.21M | -245.00K | -6.08M | -6.00K |
| Net Income | 1.88B | 2.08B | 2.40B | 1.79B | 1.15B | 712.67M | 460.81M | 269.14M | 180.91M | 175.21M | 99.66M | 67.31M | 54.24M | 97.97M | 28.34M | -24.23M | -52.03M | -11.94M | -108.80M | -156.50M |
| Net Income Ratio | 17.85% | 21.75% | 27.94% | 28.22% | 17.46% | 11.96% | 9.66% | 7.28% | 5.57% | 5.61% | 3.75% | 3.27% | 3.29% | 9.29% | 5.20% | -8.98% | -106.09% | -28.16% | -234.57% | -247.78% |
| EPS | 0.54 | 0.59 | 0.68 | 0.52 | 0.35 | 0.27 | 0.21 | 0.13 | 0.09 | 0.09 | 0.05 | 0.03 | 0.03 | 0.07 | 0.02 | -0.02 | -0.05 | -0.01 | -0.11 | -0.75 |
| EPS Diluted | 0.54 | 0.59 | 0.68 | 0.52 | 0.34 | 0.26 | 0.19 | 0.12 | 0.09 | 0.09 | 0.05 | 0.03 | 0.03 | 0.07 | 0.02 | -0.02 | -0.05 | -0.01 | -0.11 | -0.75 |
| Weighted Avg Shares Out | 3.51B | 3.54B | 3.55B | 3.45B | 3.28B | 2.69B | 2.48B | 2.31B | 2.21B | 1.97B | 1.96B | 1.96B | 1.93B | 1.49B | 1.32B | 1.29B | 1.12B | 1.12B | 1.01B | 207.99M |
| Weighted Avg Shares Out (Dil) | 3.51B | 3.54B | 3.55B | 3.45B | 3.37B | 2.79B | 2.48B | 2.31B | 2.21B | 2.01B | 1.96B | 1.96B | 1.93B | 1.49B | 1.32B | 1.29B | 1.12B | 1.12B | 1.01B | 207.99M |
Source: https://incomestatements.info
Category: Stock Reports